In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …

Immunotherapy aiming at suppressing tumor development by relying on modifying or
strengthening the immune system prevails among cancer treatments and points out a new …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Abstract B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …

Immunosurveillance is a critical mechanism guarding against tumor development and
progression. Checkpoint inhibitors have shown significant success in cancer treatment, but …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …

Simple Summary The tumor immune escape mechanisms are key factors in cancer
progression and metastasis. They are an undeniable hurdle for successful cancer treatment …

Identifying the mechanisms underlying the regulation of immune checkpoint molecules and
the therapeutic impact of targeting them in cancer is critical. Here we show that high …

Abstract B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may
be a promising target for cancer treatment. B7-H3 protein was demonstrated to be …